Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by MartialArtson May 15, 2018 2:55pm
161 Views
Post# 28034388

New position at 16.5 cents

New position at 16.5 cents
I am a big fan of CBD research.  Invested in a small sub $20 microcap PAS but I'm thinking KALY is further down the road with its Phase 2 going to Phase 3.

At 16.5 cents has a market cap of $29M on 170M shares.  I feel sorry for those who bought higher because of the past dillution and hopefully that will stop.  With Echelon at 13 cents and a double bottow at 13.5 cents earlier this month, this feels like a good place to get in for a speculative CBD based healthcare position.

They have two patents which is impressive and a fair amount of credibility with medical members on board.

On the trade, this looks good to buy at 16.5 cents. Highly speculative stock in a speculative sector so it's money I can afford to lose or get a serious haircut on.  If bears have better plays, please let me know.  I don't fall in love. I'm here simply for the money.

Level 2 Quote

Market Depth Orders/Shares Bid Price   Ask Price Shares/Orders Market Depth
  23 / 488,500 0.16   0.165 17,500 / 3  
  17 / 287,000 0.155   0.17 231,500 / 15  
  22 / 153,500 0.15   0.175 156,500 / 9  


Bullboard Posts